Latest news, announcements, etc

Showing posts with label Diabetes. Show all posts
Showing posts with label Diabetes. Show all posts
Thursday, July 25, 2013

Scientists believe proteins targeted by Botox hold diabetes answer

Scientists: It is hoped the research will lead to a treatment for diabetes.© STV


Scientists believe the proteins targeted by Botox could hold the answer to treating type two diabetes.

Researchers at Heriot-Watt University in Edinburgh are using molecular microscopic techniques on SNARE proteins to see how insulin release is regulated.


It is hoped they will identify how the regulation changes during type two diabetes.


SNARE proteins are targeted by Botox, preventing them from helping muscles contract.


They are also used in the pancreas to help release insulin. Type two diabetes happens when the cells cannot cope with prolonged high glucose levels of obese patients and releases less insulin. The reasons for this are still unclear.


It is hoped that by monitoring SNARE proteins they can determine why this happens.


Dr Colin Rickman said: "The human body has a system for storing glucose and releasing it when the body needs energy. This system controlled by the release of insulin.


"When a person is obese, which a worryingly high and increasing number of people in the UK are, this system is put under pressure and eventually fails. This leads to Type 2 diabetes. We know SNARE proteins are responsible for insulin secretion, but it's still not understood exactly how they do it.


"Once we can understand how these proteins behave in 'normal' circumstances, how they move, how they are arranged in the cell, how they interact with other proteins, we can then compare it with what happens under Type 2 diabetic conditions. This is the first time these proteins have ever been observed in such detail.


"Ultimately this could lead to new methods of diagnosis, prevention of the cells' failure that leads to diabetes and also treatments for Type 2 diabetes."


25.8 Million Diabetes Patients Need What Grove Instruments Is Developing

Grove Instruments is developing a pocket-sized device so diabetes patients can measure their glucose levels without taking their own blood. If clinical trials go well in 2013, its CEO expects to initiate the process of seeking Food and Drug Administration (FDA) approval for the device in 2014. And if that goes well, Worcester, Mass.-based Grove Instruments' product could become available for use by the 25.8 million U.S. children and adults with diabetes by 2015 or 2016.


In a July 24 interview with CEO, Arthur Combs, I learned that his previous experience makes him a very strong leader for Grove Instruments. Combs was a critical care physician in the intensive care unit during a very invasive phase of medicine - e.g., cutting open peoples' chests to do heart surgery - before joining Mallinckrodt where he rose to Executive VP, R&D. He then led three medical device start-ups before joining Grove Instruments in 2007.


By the time Combs joined, Grove Instruments had been around for 16 years. "Grove's Chief Scientist, Dr. Hannu Harjunmaa of Finland and now-retired Worcester Polytechnic Institute professor, Robert A. Peura, independently identified the importance of the Optical Bridge approach to noninvasive glucose determination. Peura has a personal passion for this because two of his children have Type 1 diabetes and lance their fingers to test their blood sugar 10 to 12 times daily. But the company was run more like a science project until the early 2000s," explained Combs.


By the time Combs joined the company, it was much closer to commercialization. "Grove had developed two devices - for the earlobe and fingertip. It was getting good clinical results even though they were not up to FDA or international standards. But they had done enough to convince me that the technology could be commercialized. The first thing I did when I joined was to build Grove Instruments' organization. I built the team from four people to 14 plus consultants and five full-time interns and we now have 5,000 square feet of office space," said Combs.


It was the optical bridge technology that makes Grove Instruments' product so much better than the competition. According to Combs, "Many companies are using a laser to send out light with a specific wavelength to detect glucose in the blood. The laser generates a specific wavelength of light that is absorbed in a stoichiometric fashion by glucose molecules - the more glucose molecules; the more photons are absorbed. The problem is that people are at least 50 percent water which absorbs the light and is not useful for detecting glucose. But our Optical Bridge technology - which has nine issued patents and four pending - negates that background water and increases the signal to noise ratio by a factor of 1,500."


Grove Instruments' product is therefore much more effective than competitors'. But Grove Instruments' product is not yet ready to be sold to the public. As Combs explained, "We have completed a trial at U Mass Medical Center and are starting another trial at Yale University. We will do more trials at Yale, U Mass and other places in 2013."


This would set the stage for FDA approval efforts. "If those trials go well, we should be in a position to begin FDA testing starting in 2014. The FDA has very specific requirements including making sure that we test the exact product we will be selling - instead of a prototype; that we follow Good Manufacturing Practice standards; that we test the product under FDA clinical practice standards; and that we follow FDA design standards. Depending on whether we form a partnership to do this testing, we could complete the FDA approval process in 2015 or 2016," said Combs.


Grove Instruments is burning through cash and needs to raise more. According to Combs, "Throughout the company's history it has raised about $25 million to $30 million. This includes grants from the National Institute of Health and a prize from the Massachusetts Life Sciences Collaborative. I am raising funds now from private equity investors that should last us through June 2014. Wealthy individuals in 12 states are willing to invest because they have a personal connection with diabetes - regardless of the general economic climate."


If Grove Instruments succeeds, the number of daily finger lances by the U.S.'s diabetes patients would plunge below its current 310 million. And that would be a big step in the right direction for non-invasive medicine.


Diabetic kidney disease

With an aging society and increase in obesity, the number of diabetes patients is increasing each year. This is associated with an increase in chronic complications of diabetes.


Diabetic kidney disease is the most common cause of end-stage renal disease, and is the most serious complication of diabetic patients. Therefore, the presence of diabetic kidney disease is an important prognostic factor for diabetic patients. Here, I will discuss the risks, prevention and management of diabetic kidney disease.


How is diabetes related to the kidneys?


The chronic elevation of blood glucose in diabetic patients leads to various complications. The complications of diabetes can be divided into macrovascular and microvascular complications. The kidneys contain small blood vessels, and are the main organ affected by diabetes.



(Illustration by Park Gee-young)


Diabetic kidney disease leads to proteinuria in the early stages, and gradually leads to declining kidney function. This in turn leads to various problems including accumulation of waste products, electrolyte disturbance and anemia.


Who develops diabetic kidney disease and how can it be prevented?


The prevalence of diabetic kidney disease in type 1 and 2 diabetic patients is approximately 30 percent. Diabetic kidney disease usually arises after five years of having diabetes. Those with type 2 diabetes have a higher chance of developing the disease earlier, which is why they should be aware of kidney disease from the diagnosis of diabetes.


Diabetic kidney disease is more common in those with higher blood glucose levels, those with obesity, and those who are smokers. The disease tends to progress more quickly in these people. Therefore, it is important to manage these risk factors to prevent diabetic kidney disease. Strict management of blood glucose, weight control and not smoking can help prevent the progression of diabetic kidney disease.


How can kidney complications be identified in diabetic patients?


There are no objective symptoms of early kidney disease. Often, in diabetic kidney disease, the absence of symptoms does not necessarily indicate the absence of any kidney problems. Therefore, diabetic patients need regular tests for complications.


The earliest indication of diabetic kidney disease is microalbuminuria, which can be identified by urine tests. Patients with type 1 diabetes should have tests for microalbuminurias every year starting 5 years after diabetes diagnosis, whereas patients with type 2 diabetes should be tested every year from the time of diagnosis. The presence of albumin in urine suggests diabetic kidney disease.


However, some people may have declining kidney function without albuminuria, which is why serum creatinine levels are also measured to assess kidney function. Patients with diabetic kidney disease often also develop hypertension, so the diabetic patients with hypertension should be observed closely for the development of diabetic kidney disease. Diabetic kidney disease can lead to edema and nocturia in its late stages. However, these are also caused by other diseases, which is why the patient needs to be tested further to make the diagnosis.


I have been diagnosed with kidney complications while under management for diabetes. What do I need to do now?


Once you develop diabetic kidney disease, efforts should be made to delay its progression rather than trying to achieve a cure. Diabetic kidney disease progresses gradually, but the rate of progression varies widely. It can be delayed by using appropriate medication and making lifestyle changes. The most important thing is to manage your blood glucose levels.


Hyperglycemia increases the risk of developing diabetic kidney disease, and contributes to the progression of the disease, which is why it is so important to manage blood glucose levels. To do this, you should maintain a regular and appropriate diet, as well as regular exercise. You should also be prescribed diabetic medications and insulin by your doctor. The target blood glucose level is 70-130 fasting, under 180 two hours after a meal, and HbA1c of 7 or less.


The second important thing is managing your blood pressure. Patients with diabetic kidney disease often have hypertension, and uncontrolled hypertension can lead to worsening of proteinuria and significant decline in kidney function. Control of blood pressure may be easier than controlling diabetes, and the effect of blood glucose is more significant on the kidneys, which is why managing blood glucose may be more important than managing hypertension. For effective control of blood pressure, it is important to maintain a low-salt diet, exercise regularly and lose weight. The salt intake per day should be 2.3 grams or less for a low-salt diet. You can try the following to eat a low-salt diet: use soy sauce, garlic, onions or lemon instead of salt when cooking. Cook food without using salt, then add salt as needed before eating. Check the salt content of foods when purchasing foods, and write a food diary.


It is also important to use antihypertensive medicines together with dietary modification. A certain class of antihypertensive agents may be helpful, so you should discuss this with your doctor. Often, a single type of antihypertensive may not be sufficient to reach the target blood pressure, so you may need several types of antihypertensives. The target blood pressure is 130 mmHg systolic, and 80 mmHg diastolic.


Smoking is a major factor that contributes to the progression of diabetic kidney disease and can cause cardiovascular complications, so you should stop smoking. The aim of diabetic kidney disease treatment is to prevent the progression of renal failure, while also preventing the development of cardiovascular complications. For this, you should manage blood pressure and blood glucose, and make lifestyle modifications. There is no definitive treatment for diabetic kidney disease, so you should avoid using untested treatments without discussing this with your doctor.


Lastly, if you already have late-stage renal failure from diabetic kidney disease, it is recommended that you undergo dialysis treatment at an appropriate time. This is because renal failure leads to accumulation of waste products that can cause serious problems in not only the kidneys, but also other organs. A kidney transplant is another option for diabetic patients, so make sure that you discuss all the options with your specialist doctor.



Lee Jung-eun


By Lee Jung-eun


The author is a doctor in the Division of Nephrology at Samsung Medical Center and a professor of Sungkyunkwan University School of Medicine. ― Ed.


Baxter the diabetes dog will get his life

Baxter the black lab is Ali Saber's lifeline - alerting her when her blood sugar dips dangerously low - and now, thanks to generous donations, he will soon begin cancer treatments.


Saber and Baxter have been together for ten years. When Saber is sleeping and her blood sugar dips dangerously low, Baxter can smell it on her breath and nudges her awake so she can check her blood sugar.


"About two and a half months ago, I noticed a lump on his side," she said. "Sure enough the report came back and it's cancer."


Saber borrowed the money to have the tumor removed. But Baxter still needs injections and medication she can't afford. So she took the story public and donations began coming in.


"The response has been great and is very heart warming," veterinarian Lisa Parshley said Wednesday. Parshley said enough money has been raised to provide therapy for the next 6 months. "It is hard to know before starting how Baxter will respond to therapy and how long he might need to be on therapy. If he responds he has a chance at several years," she said.


Anyone interested in making a donation can do so through the Paws Against Cancer charity or contact Dr. Tom Allen at Olympia Veterinary Cancer Center at (360) 339-3596.


Pets and Animals Video More Video

Baxter the diabetes dog will get his life

Baxter the black lab is Ali Saber's lifeline - alerting her when her blood sugar dips dangerously low - and now, thanks to generous donations, he will soon begin cancer treatments.


Saber and Baxter have been together for ten years. When Saber is sleeping and her blood sugar dips dangerously low, Baxter can smell it on her breath and nudges her awake so she can check her blood sugar.


"About two and a half months ago, I noticed a lump on his side," she said. "Sure enough the report came back and it's cancer."


Saber borrowed the money to have the tumor removed. But Baxter still needs injections and medication she can't afford. So she took the story public and donations began coming in.


"The response has been great and is very heart warming," veterinarian Lisa Parshley said Wednesday. Parshley said enough money has been raised to provide therapy for the next 6 months. "It is hard to know before starting how Baxter will respond to therapy and how long he might need to be on therapy. If he responds he has a chance at several years," she said.


Anyone interested in making a donation can do so through the Paws Against Cancer charity or contact Dr. Tom Allen at Olympia Veterinary Cancer Center at (360) 339-3596.


Pets and Animals Video More Video

All welcome at diabetes hui


Arowhenua Health Clinic nurse Maree Rowley knows that diabetes is a disease that steals quality of life.


She also knows that educating people is key to understanding, and understanding is key to improving health.


That is why the health clinic is holding a hui on the subject, and everyone is invited - Maori and non-Maori, people with or without diabetes, young and old.


Mrs Rowley said diabetes is a lifestyle disease.


"Smoking, not exercising, diet, weight, age, ethnicity are all contributing factors," she said.


"Until I started studying my post-graduate certificate in diabetes I didn't realise it is such a huge disease.


"You hear adverts drone on about diabetes, but I didn't realise how it robs people of their quality of life. It robs people not just personally, but it costs their contribution to the workforce, their families and communities,- personally and financially.


"I'll do anything I can to reduce that cost.


"The more information people have the more they can manage themselves and trip-ups become fewer. It's about giving them information and letting them make choices."


Small hui have been held monthly and attendance had mostly been gained through word of mouth, but the upcoming meeting is expected to be bigger and better.


Community dietician Tim Brosnahan will be speaking about packaging labels.


"Food labels can sometimes be helpful and not so helpful," Mrs Rowley said.


Arowhenua Health Clinic GP Dr Tahir Ayub will also be speaking and answering questions.


"Knowing what the concerns are and education is king, we need to be proactive rather than reactive. This opportunity is free, it's open to anybody, and anyone who is educated about diabetes and makes changes and choices to improve their overall health, that has to be a good thing," Mrs Rowley said.


Although Arowhenua Whanau Services is Maori-based, Mrs Rowley wants to make it clear that it is open to everyone.


"It's absolutely not exclusive. Any Tom, Dick, or Harry is more than welcome, so is their family, their whanau, friends ... anyone.


"I think some people feel that if they come out to Arowhenua they're unsure, they feel like they might do something wrong.


"I've always found everyone welcoming and warm and wonderful really. And I've never been frightened to ask if I'm unsure," Mrs Rowley said.


Arowhenua Whanau Services is funded by the South Canterbury District Health Board, and is a nurse-led clinic that provides free healthcare to anyone who needs it.


Mrs Rowley encourages more people to make the most of the service.


The Hui will be held at the Arowhenua Marae from 2pm to 4pm on August 14. Attendees are asked to bring a can or a packet of non-perishable food to study the label.


It will then be collected and donated to families in need.


SOUTH CANTERBURY HERALD - © Fairfax NZ News Comments

Summer camp a reality for children with diabetes


Children diagnosed with diabetes at Camp Easter Seal in Manitou Beach, Saskatchewan this week. Brent McGillivray / Global News


WATROUS, Sask. - For over 50 years, 64 kids diagnosed with type 1 diabetes from around Saskatchewan have had the opportunity to go to camp at Manitou Beach.


The camp gives them a summer experience with other kids who understand the day to day challenges of diabetes.


"Dr. Best is my doctor in Saskatoon. So I go see him once a year and he showed me a photo book of kids having fun at camp and I didn't know there was a camp special for diabetics, so I thought I'd come try it out and I've loved it ever since," said Joseph Hodgson, 12-year-old diabetic.


The Canadian Diabetes Association has been making summer camps a reality for kids with diabetes for over 50 years.


"They learn how to test their blood sugars themselves, they learn how to adjust their insulin levels, depending on their activity levels and what they're going to be eating that day, how much to eat. All that kind of thing, that probably their parents managed and this is the opportunity for them to learn on their own," said Brie Hnetka, Canadian Diabetes Association.


Over 80,000 people in Saskatchewan are dealing with type 1 or 2 diabetes, according to the Canadian Diabetes Assocation.


It's estimated that by 2020, the number could reach over 110,000, equivalent to 10 percent of the population.


Hi-Tech Pharmacal gets FDA warning on diabetes meds


Hi-Tech Pharmacal Co. said Wednesday it would comply with a federal warning about three of its medicinal creams for diabetics.

The Amityville-based manufacturer of generic and brand-name drugs said it had received a "warning letter" from the federal Food and Drug Administration on July 15. The letter "related to certain statements that appear in labeling" on the creams, the company said.

In the letter, the FDA said Hi-Tech's claims about the creams make them drugs subject to FDA approval, which has not been granted.

The FDA said sale of the creams across state lines was prohibited without first receiving federal approval.

The creams are Diabeti-Derm Antifungal Cream and Zostrix Diabetic Foot Pain Relief Cream and Diabetic Joint & Arthritis Pain Relief Cream.

The three generated $1.1 million in sales for the fiscal year ended April 30. Hi-Tech's total sales for the year were $232 million.

Hi-Tech is one of 15 companies accused by the FDA Tuesday of marketing illegal treatments for diabetes. In announcing the nationwide crackdown, the FDA said, "consumers should exercise caution before using products claiming to be herbal or all-natural alternatives to FDA-approved prescription drugs. These products should be considered unsafe and should not be used."

Hi-Tech made its announcement came this morning's stock market's opening. In early trading, Hi-Tech shares were down 43 cents, or more than 1 percent, to $36.15.

Be the first to rate:

Click to rate

16% of Qatar's adult population suffers from diabetes


People taking part in the diabetes screening.


About 16% of the adult Qatari population between the age of 20 and 79 suffers from diabetes, according to a statement issued by Action on Diabetes (AOD). AOD is a joint initiative by the Supreme Council of Health, Hamad Medical Corporation ( HMC), Qatar Diabetes Association, Maersk Oil and world leader in diabetes care Novo Nordisk.Action on Diabetes (AOD) recently completed the public screening campaigns that have been running across malls in Doha last month. As a reaction to these growing numbers, the AOD public screening campaign focused on reaching out to Qatar's local population and providing free diabetes testing as well as guidance by professional dieticians from the Qatar Diabetes Association and Hamad Medical Corporation through a specialist screening booth placed in various malls across Qatar.The results of the screenings suggest that a high percentage of Qatar's residents have too high blood sugar levels. Out of the 2,785 individuals that were screened during the campaign, 553 individuals had diabetes or showed abnormal high levels of blood sugar. The alarming fact was that 86% of the individuals tested, were unaware that they had abnormal high blood sugar. All individuals at risk of developing diabetes had a consultation with a diabetes educator and were referred to adequate health care at assigned centres and physicians.Raising awareness about diabetes and the need to be regularly screened was one of the main objectives of the campaign as early detection is able to stop the onset of the disease which is currently rising at record rates in Qatar. Dr Mahmoud Zirie, head of Endorcinology at HMC, said: "The campaign highlighted that the number of people in Qatar who are unaware of their diabetes condition or are pre-diabetic is rather high. By 2030, it is estimated that the number of people with diabetes will almost double. However, with initiatives such as the screening campaign, we are trying to significantly lower these numbers through education, early detection and intervention."Working to raise the general awareness of diabetes, with particular focus on increasing public knowledge and understanding of the risk factors involved, AOD aims at informing and encouraging the community in Qatar to make real life-style changes that make a difference both to those who already have diabetes, but also in preventing those at risk from developing it in the future.Dr Abdulla al-Hamaq, director of Qatar Diabetes Association, member of Qatar Foundation, commented, "Diabetes prevention is in your hands - this is the message we want to deliver and hope that this screening campaign has gone someway in really making this point. Diabetes screening tests are a good preventive method for catching the development of diabetes at an early stage."AOD has also launched a 'Fasting & Health' daily programme running throughout the holy month of Ramadan on the Qur'an station 103.4FM, from Sunday to Thursday at 13:00. The hour-long programme aims at giving medical lessons on how to deal with difficult health situations during Ramadan.


FDA warns 15 firms to stop selling illegal diabetes remedies

Posted: Wednesday, July 24, 2013, 1:08 AM



WASHINGTON - The Food and Drug Administration is cracking down on more than a dozen companies that market illegal diabetes treatments, ranging from bogus dietary supplements to prescription drugs sold online without a prescription.


The products aim to cash in on the country's diabetes epidemic, which affects nearly 26 million Americans. Regulators worry that consumers who buy such unapproved products could put off getting legitimate medical care.


The FDA sent warning letters to 15 companies, here and abroad, ordering them to stop selling diabetes treatments that violate U.S. drug laws.


Three of the products targeted are marketed as "natural" supplements, but actually contain unlisted pharmaceutical ingredients. For example, Diexi, sold as a traditional Indian "herbal formula," contains metformin, the most common prescription drug used to treat diabetes. The product is sold by Amrutam Life Care of Surat, India.


"Consumers should exercise caution before using products claiming to be herbal or all-natural alternatives to FDA-approved prescription drugs," the agency said in a statement Tuesday. "These products should be considered unsafe and should not be used."


Other products include genuine dietary supplements that make unproven claims to treat or prevent diabetes. For example, Diabetes Daily Care is a capsule-based supplement containing cinnamon extract and other herbs. Its manufacturer, Nature's Health Supply Inc., claims it "safely and effectively improves sugar metabolism."


Under U.S. law, only FDA-approved medicines are permitted to make claims for treating or preventing disease.


Other companies targeted by the FDA run online pharmacies that sell drugs for diabetes without a prescription. The FDA issued a warning letter to www.bestcheapmedsonline.com for marketing unapproved versions of diabetes drugs like Januvia, from Merck & Co.


The FDA warns against buying prescription medications on the Internet. Only 3 percent of online pharmacies comply with all U.S. laws, according to a review by the National Association of Boards of Pharmacy.


Wednesday, July 24, 2013

FDA targets 15 companies for marketing bogus, unapproved diabetes treatments


This undated photo provided by The Food and Drug Administration (FDA) shows Diexi, which is sold as a traditional Indian "herbal formula," which actually contains metformin, the most common prescription drug used to treat diabetes. ( AP Photo/FDA)


WASHINGTON - The Food and Drug Administration is cracking down on more than a dozen companies that market illegal treatments for diabetes, ranging from bogus dietary supplements to prescription drugs sold online without a prescription.


All of the products aim to cash in on the country's diabetes epidemic, which affects nearly 26 million Americans. Regulators worry that consumers who buy such unapproved products could put off getting legitimate medical care, which could exacerbate heart disease, kidney failure and other deadly complications.


The FDA sent warning letters to 15 companies, both in the U.S. and abroad, ordering them to stop selling diabetes treatments which violate U.S. drug laws.


Three of the products targeted are marketed as "natural" supplements, but actually contain unlisted pharmaceutical ingredients. For example, Diexi, which is sold as a traditional Indian "herbal formula," actually contains metformin, the most common prescription drug used to treat diabetes. The product is sold by Amrutam Life Care, of Surat, India.


"Consumers should exercise caution before using products claiming to be herbal or all-natural alternatives to FDA-approved prescription drugs," the agency said in a statement Tuesday. "These products should be considered unsafe and should not be used."


Other products include genuine dietary supplements that make unproven claims to treat or prevent diabetes. For example, Diabetes Daily Care is a capsule-based supplement containing cinnamon extract and other herbs. Its manufacturer, Nature's Health Supply Inc., claims it "safely and effectively improves sugar metabolism."


Under U.S. law, only FDA-approved medicines are permitted to make claims for treating or preventing disease.


Other companies targeted by the FDA run online pharmacies that sell prescription drugs for diabetes without a prescription. The FDA issued a warning letter to http://www.bestcheapmedsonline.com for marketing unapproved versions of diabetes drugs like Januvia, from Merck & Co. Inc.


The FDA warns patients against buying prescription medications on the Internet. Only 3 per cent of online pharmacies actually comply with all U.S. pharmacy laws, according to a review by the National Association of Boards of Pharmacy.


People with diabetes are unable to properly break down carbohydrates, either because their bodies do not produce enough insulin or because they've become resistant to the hormone, which controls blood sugar levels. These patients face higher risks of heart attacks, kidney problems, blindness and other serious complications.


Many diabetics require multiple drugs to control their blood sugar levels.


The U.S. market for prescription diabetes drugs is the largest in the world, with sales of $22 billion last year. Sales have ballooned more than 60 per cent in the last four years from $13.6 billion in 2008, according to health data firm, IMS Health.


The FDA said it has not received any reports of injury or illness connected with the products, but is taking action as a precautionary measure.


The FDA sent the warning letters to the companies last week, but posted them online Tuesday morning. The letters gives each company 15 business days to reply and explain how they will come into compliance with U.S. law. FDA warning letters are not legally binding, but the agency can take companies to court if they are ignored.


Diabetes 'linked to disability risk'


Adults with diabetes have a higher risk of physical disability, research shows.


Older people with diabetes are 50% to 80% more likely to develop a physical disability than those without, according to a review of 26 studies.


No distinction was made between type-1 and type-2 diabetes, but most of the data involved people over the age of 65, who are more likely to have type-2.


Ensuring all people with diabetes have access to the right care is hugely important, said a diabetes charity.


The study, published in the journal the Lancet Diabetes & Endocrinology, reviewed data from thousands of patients around the world.


Disability was defined as impaired mobility and the inability to perform normal activities such as bathing, eating, shopping or using transport.


The Australian researchers say the reasons behind the link are unclear, but high blood sugar levels may lead to muscle damage over time.


"The complications associated with diabetes, such as heart disease, stroke, and kidney disease, can all result in disability," said study leader Dr Anna Peeters and Dr Evelyn Wong, of the Baker IDI Heart and Diabetes Institute in Melbourne.


"As the world's population ages, and diabetes becomes more common, it seems clear that we will see an increased need for disability-related health resources, which health systems around the world need to be prepared for."


Previous studies have given a confusing picture of the scale of the link between diabetes and disability, with estimates ranging from zero risk to double.


Dr Edward Gregg, of the Centers for Disease Control and Prevention, in Atlanta, US, said the new analysis was the first to quantify the extent of disability diabetes causes.


"We are going to need to think about preventing disability as one of our priorities in managing and dealing with diabetes," he said.


The charity Diabetes UK said the research showed yet again that diabetes complications could result in serious life-limiting disability.


Head of research, Dr Matthew Hobbs, said: "It emphasises why preventing type-2 diabetes and ensuring that all people with diabetes have access to the right care is so hugely important. "


The link may be explained by the fact that complications caused by consistently high blood glucose levels, such as amputation, blindness, heart disease and stroke were, themselves, major causes of disability, he said.


Another possible explanation is that risk factors for type-2 diabetes, such as being overweight, also increase the likelihood of disability.


"Eating a healthy, balanced diet and being more physically active in your daily life can help to reduce your risk of developing type-2 diabetes," said Dr Hobbs.


FDA cracks down on illegal diabetes Rx


WASHINGTON - The Food and Drug Administration is cracking down on more than a dozen companies that market illegal treatments for diabetes, ranging from bogus dietary supplements to prescription drugs sold online without a prescription.


All of the products aim to cash in on the country's diabetes epidemic, which affects nearly 26 million Americans. Regulators worry that consumers who buy such unapproved products could put off getting legitimate medical care, which could exacerbate heart disease, kidney failure and other deadly complications.


The FDA sent warning letters to 15 companies, both in the United States and abroad, ordering each to stop selling diabetes treatments which violate U.S. drug laws.


Three of the products targeted are marketed as natural supplements, but actually contain unlisted pharmaceutical ingredients. For example, Diexi, which is sold as a traditional Indian "herbal formula," actually contains metformin, the most common prescription drug used to treat diabetes. The product is sold by Amrutam Life Care, of Surat, India, the FDA said.


"Consumers should exercise caution before using products claiming to be herbal or all-natural alternatives to FDA-approved prescription drugs," the agency said in a statement Tuesday. "These products should be considered unsafe and should not be used."


Other products include genuine dietary supplements that make unproven claims to treat or prevent diabetes. For example, Diabetes Daily Care is a capsule-based supplement containing cinnamon extract and other herbs. Its manufacturer, Nature's Health Supply Inc., claims it "safely and effectively improves sugar metabolism," the FDA said.


Under U.S. law, only FDA-approved medicines are permitted to make claims for treating or preventing disease.


Other companies targeted by the FDA run online pharmacies that sell prescription drugs for diabetes without a prescription. The FDA issued a warning letter to www.bestcheapmedsonline.com for marketing unapproved versions of diabetes drugs like Januvia, from Merck & Co. Inc.


The FDA warns patients against buying prescription medications on the Internet. Only 3 percent of online pharmacies actually comply with all U.S. pharmacy laws, according to a review by the National Association of Boards of Pharmacy.


People with diabetes are unable to properly break down carbohydrates, either because their bodies do not produce enough insulin or because they've become resistant to the hormone, which controls blood sugar levels. These patients face higher risks of heart attacks, kidney problems, blindness and other serious complications.


Many diabetics require multiple drugs to control their blood sugar levels.


The U.S. market for prescription diabetes drugs is the largest in the world, with sales of $22 billion last year. Sales have ballooned more than 60 percent in the last four years from $13.6 billion in 2008, according to health data firm, IMS Health.


The FDA said it has not received any reports of injury or illness connected with the products, but is taking action as a precautionary measure.


The FDA sent the warning letters to the companies last week, but posted them online Tuesday morning. The letters gives each company 15 business days to reply and explain how they will come into compliance with U.S. law. FDA warning letters are not legally binding, but the agency can take companies to court if they are ignored.


Be the first to rate:


Click to rate


Merck's $5.7 Billion Diabetes Franchise Vulnerable

A retrospective analysis published by the BMJ supports previously published findings that diabetic patients taking drugs which target the incretin system to control their blood sugars are at greater risk for developing pancreatic problems, such as acute pancreatitis and pancreatic cancer. Could certain big pharma manufacturers be vulnerable to a price collapse, should European and U.S. regulators - whom are now actively reviewing data on adverse events - move to restrict usage or outright remove these therapies from the market due to questionable safety?



MRK Total Return Price data by YCharts


Incretin-based therapies, such as GLP-1 agonists and dipeptidylpeptidase-4 (DDP-4) inhibitors, mimic the glucose regulating role of intestinal hormones. As they carry a lower risk of hypoglycemia and have observed weight-loss properties, the two drug classes have readily been adopted by physicians for treating type-2 diabetes, with several drugs rapidly growing annual sales in the estimated $40 billion market for diabetes control medications.



MRK Revenue Annual data by YCharts


As Merck ( MRK) looks to reset its revenue base due to patent losses, its DDP-4 inhibitor, Januvia (sitagliptin), remains critical to its financial health. In FY 2012, global sales of the combined diabetes franchise of Januvia/Janumet (which contains the popular type-2 diabetes drug metformin) grew 23% to $5.7 billion, primarily driven by growth in the United States and Japan. A global ban would wipe out more than 12% of the drug maker's annual sales!


Though Novartis' ( NVS) DDP-V inhibitor Galvus delivered 34% growth in 2012, its $910 million in sales accounted for less than 2% of the $57 billion in annual drug sales. The Swiss-based company's growth engines are fueled by oncology and neuroscience drugs, such as Gleevec and Gilenya (multiple sclerosis).


The consumer advocacy group Public Citizen has petitioned the FDA to remove Novo Nordisk's ( NVO) Victoza (liraglutide). Albeit the Danish-based drug maker derives almost 10% of annual sales from this GLP-1 agonist, the current safety debate could actually benefit the company: Insulin products generated almost 60% of the $11.7 billion in drug revenue last year; and, with a global insulin market share of more than 47%, any move back to mainstream diabetic treatment would likely more than offset lost sales from Victoza.


In addition to lost sales, all drug makers of incretin mimetics, including the newer DPP-4 inhibitors - Tradjenta (linagliptin) from Eli Lilly ( LLY) and Nesina (alogliptin) from Takeda - will need to put aside reserves due to the possibility of multi-million dollar injury settlements (class action lawsuits are being filed).


David J. Phillips, a contributing editor at YCharts, is a former equity analyst. His journalism has appeared in Bloomberg BusinessWeek, Forbes, and Kiplinger's Personal Finance. From 2008 to 2011, David was a reporter for CBS News Interactive. He can be reached at editor@ycharts.com. You can also request a demonstration of YCharts Platinum.

FDA warns firms selling illegal diabetes remedies

The U.S. Food and Drug Administration is cracking down on more than a dozen companies that market illegal treatments for diabetes, ranging from bogus dietary supplements to prescription drugs sold online without a prescription.


All of the products aim to cash in on the country's diabetes epidemic, which affects nearly 26 million Americans. Regulators worry that consumers who buy such unapproved products could put off getting legitimate medical care, which could exacerbate heart disease, kidney failure and other deadly complications.


Diexi, which is sold as a traditional Indian herbal formula, actually contains metformin, the most common prescription drug used to treat diabetes, the FDA says. (FDA/Associated Press)


The FDA sent warning letters to 15 companies, both in the U.S. and abroad, ordering them to stop selling diabetes treatments which violate U.S. drug laws.


Three of the products targeted are marketed as "natural" supplements, but actually contain unlisted pharmaceutical ingredients. For example, Diexi, which is sold as a traditional Indian "herbal formula," actually contains metformin, the most common prescription drug used to treat diabetes. The product is sold by Amrutam Life Care, of Surat, India.


"Consumers should exercise caution before using products claiming to be herbal or all-natural alternatives to FDA-approved prescription drugs," the agency said in a statement Tuesday. "These products should be considered unsafe and should not be used."


Other products include genuine dietary supplements that make unproven claims to treat or prevent diabetes. For example, Diabetes Daily Care is a capsule-based supplement containing cinnamon extract and other herbs. Its manufacturer, Nature's Health Supply Inc., claims it "safely and effectively improves sugar metabolism."


Under U.S. law, only FDA-approved medicines are permitted to make claims for treating or preventing disease.


Other companies targeted by the FDA run online pharmacies that sell prescription drugs for diabetes without a prescription.


The FDA issued a warning letter to bestcheapmedsonline.com for marketing unapproved versions of diabetes drugs like Januvia, from Merck & Co. Inc.


The FDA warns patients against buying prescription medications on the internet. Only 3 per cent of online pharmacies actually comply with all U.S. pharmacy laws, according to a review by the National Association of Boards of Pharmacy.


People with diabetes are unable to properly break down carbohydrates, either because their bodies do not produce enough insulin or because they've become resistant to the hormone, which controls blood sugar levels. These patients face higher risks of heart attacks, kidney problems, blindness and other serious complications.


Many diabetics require multiple drugs to control their blood sugar levels.


The U.S. market for prescription diabetes drugs is the largest in the world, with sales of $22 billion US last year. Sales have ballooned more than 60 per cent in the last four years from $13.6 billion US in 2008, according to health data firm, IMS Health.


The FDA said it has not received any reports of injury or illness connected with the products, but is taking action as a precautionary measure.


The FDA sent the warning letters to the companies last week, but posted them online Tuesday morning. The letters gives each company 15 business days to reply and explain how they will come into compliance with U.S. law. FDA warning letters are not legally binding, but the agency can take companies to court if they are ignored.


Of the products on the FDA's list, Neuragen PN and Neuragen Cream are also listed in Health Canada's natural products database.


Health Canada said it was aware of the FDA's initiative and is checking whether the products are being advertised and sold in Canada.


"Health Canada has in the past taken compliance action against unauthorized products that are illegally advertised and sold for the treatment of diabetes," a spokeswoman said in an email.


US FDA warns 15 companies over fraudulent diabetes product claims


By Toni Clarke


July 23 (Reuters) - U.S. health regulators are cracking down on 15 companies for selling products they said falsely claim to cure or mitigate the symptoms of diabetes.


The U.S. Food and Drug Administration sent letters last week to 10 domestic and five foreign companies, warning them that their products violate the law.


A total of 20 products are covered by the warning letters. In some, treatments are being sold as "natural" when in fact they contain pharmaceutical ingredients, the FDA said.


In other cases, prescription drugs are being sold to patients without a prescription; and in some cases products are falsely claiming to cure or mitigate the symptoms of the disease.


The products are being sold online and in retail outlets, the agency said, though it could not say how many stores the products are sold in or how many have been distributed online.


But Howard Sklamberg, director of the office of compliance in the FDA's drugs division, said he considers health care fraud in general, and health care fraud involving diabetes products in particular, as "a large problem."


The FDA said three of the most potentially dangerous cases it had targeted involve unapproved products originating in Asia that contain pharmaceutical ingredients not disclosed on the product labels.


These products are called Diexi, which was shipped from India, Insupro Forte, which was shipped from Malaysia, and Jiang Tan Yi Huo Su Jiao Nang, which the FDA said translates as Anti-diabetic Pancreatic Capsule and was shipped from China.


Diexi, made by Amrutam Life Care, is marketed on the company's website as an "anti-diabetic herbal formula that provides an effective treatment to relieve all symptoms related to diabetes."


According to the FDA's testing, however, Diexi contains metformin, a pharmaceutical approved in the United States to treat diabetes under a physician's supervision.


Another drug, Insupro Forte, is advertised by Easy Pha-max as "Truly Saviour of Diabetics." The company claims the product is made with a plant-based protein that helps bring down blood sugar levels and repairs physically altered cells.


In fact the product contains glyburide, an FDA-approved diabetes medication that can cause serious side effects including low blood sugar if not taken properly, the agency said.


Testing showed that the Anti-diabetic Pancreatic Capsule contained metformin, glyburide and phenformin. Phenformin was removed from the U.S. market in 1978 because it was associated with lactic acidosis, a serious condition that can cause weakness, tiredness, muscle pain, trouble breathing and a sudden slow or irregular heartbeat.


The companies could not be immediately reached for comment.


"Diabetes is a serious chronic condition that should be properly managed using safe and effective FDA-approved treatments," FDA Commissioner Margaret Hamburg said in a statement. "Consumers who buy violative products that claim to be treatments are not only putting themselves at risk but also may not be seeking necessary medical attention, which could affect their diabetes management."


Nearly 26 million Americans have the disease, which can lead to heart disease, blindness, kidney failure, and amputations of the lower limbs.


If the firms do not comply with the law, the FDA can take action to prevent the products from being imported from overseas, and it can seize those made domestically and initiate criminal proceedings. (Reporting by Toni Clarke in Washington; Editing by Ken Wills)


Tuesday, July 23, 2013

Illegal diabetes products draw 15 FDA warnings


8 minutes ago


Food and Drug Administration officials are cracking down on companies that sell illegal and fraudulent products that claim to treat, ease or even cure diabetes, which affects 1 in 9 Americans older than 20.


The agency posted warning letters on Tuesday that it sent to 15 firms in the U.S. and abroad that market unapproved supplements, creams and other so-called diabetes treatments. The firms, including online and retail stores, are peddling products that contain harmful ingredients or are otherwise unsafe, officials said. Others are selling diabetes medications without required prescriptions.


"These people are fraudsters who are scamming people and creating risks that people are going to get very sick," said Howard Sklamberg, director of the Office of Compliance in the FDA's Center for Drug Evaluation and Research.


Targeted products include Zostrix Diabetic Foot Pain Relief Cream, DiabeRex, marketed as "the New Diabetes Miracle," and Glytain, billed as "the all-natural way to support normal blood sugar levels".


The agency has received no reports of serious adverse events linked to the products and Sklamberg said officials have no way of knowing how many of the nearly 26 million Americans with diabetes may have used them.


The danger, however, is that people who don't know better will take the products instead of seeking medical help for the potentially life-threatening condition, said Dr. Karen Mahoney, an FDA safety reviewer.


"All patients with diabetes need to be under the care of a licensed health care professional," Mahoney told NBC News. "You need to go to a doctor. If they're taking on one of these products, they should stop."


Diabetes is a disease that causes blood sugar levels to rise higher than normal because the body does not produce sufficient amounts of insulin or to use its own insulin efficiently. Untreated, or treated improperly, it can lead to serious problems including heart disease, kidney failure, blindness and lower-extremity amputations.


Targeted firms and products include the following:


· Diexi by Amrutam Life Care Pvt. Ltd., Surat India.


· Anastasia Diapedic Foot & Leg Treatment by Anastasia Marie Laboratories Inc., Oklahoma City, Okla.


· Exermet GM, Galvus, Nuzide, Triexer and unapproved versions of Januvia, all from www.bestcheapmedsonline.com.


· Diaberex by Enhance Nutraceutical.


· Zostrix Diabetic Foot Pain Relief Cream, Zostrix Diabetic Joint & Arthritis Pain Relief Cream and Diabeti-Derm Antifungal Cream, all from Health Care Products, Hi-Tech Pharmacal Co., Amityville, N.Y.


· Sugar Balancer by Health King Enterprises & Balanceuticals Group Inc., Chicago.


· Insupro Forte by INS Bioscience Berhad, HLS International Sdn. Bhd., Easy Pha-max, Selangor Darul Ehsan, Malaysia.


· Diabetic Neuropathy Foot Cream, Diabetic Foot Cream, and Diabetic Hand & Body Cream by The Magni Group, doing business as MagniLife, McKinney, Texas.


· Eradicator by Naturecast Products, Coral Springs, Fla.


· Diabetes Daily Care by Nature's Health Supply Inc., College Park, Md.


· Glucocil by Neuliven Health, San Diego,Calif.


· Neuragen PN and Neuragen Cream by Origin BioMed Inc., Halifax, Novia Scotia, Canada.


· Nepretin by Nutrient Synergy, Longmont, Colo.


· ProBeta by PharmaTerra Inc., Bellevue, Wash.


Beware of Illegally Sold Diabetes Treatments

Get Consumer Updates by E-mail On this page: Print and share (PDF 173K) Consumer Updates RSS Feed

Sound too good to be true? Then it's probably a scam. Watch out for these and similar red flags:


"Lowers your blood sugar naturally!" "Inexpensive therapy to fight and eliminate type II diabetes!" "Protects your eyes, kidneys, and blood vessels from damage!" "Replaces your diabetes medicine!" "Effective treatment to relieve all symptoms of diabetes!" Watch this video to learn more: Go to Flickr for these captioned photos of illegally sold diabetes treatments:

As the number of people diagnosed with diabetes continues to grow, illegally sold products promising to prevent, treat, and even cure diabetes are flooding the marketplace.


The Food and Drug Administration (FDA) is advising consumers not to use such products. They may contain harmful ingredients or may be otherwise unsafe, or may improperly be marketed as over-the-counter (OTC) products when they should be marketed as prescription products. They carry an additional risk if they cause consumers to delay or discontinue effective treatments for diabetes. Without proper disease management, people with diabetes are at a greater risk for developing serious health complications.


"People with chronic or incurable diseases may feel desperate and become easy prey. Bogus products for diabetes are particularly troubling because there are effective options available to help manage this serious disease rather than exposing patients to unproven and risky products," said Gary Coody, R.Ph., national health fraud coordinator for FDA. "Failure to follow well-established treatment plans can lead to, among other things, amputations, kidney disease, blindness and death."


Warning Letters Issued

Recently, FDA launched an initiative to counter these illegally sold products aimed at consumers who have diabetes. In addition to evaluating numerous consumer complaints, FDA surveyed the marketplace for illegally sold products promising to treat diabetes and its complications.


In July 2013, FDA issued letters warning 15 companies about selling products for diabetes in violation of federal law. These products are sold as dietary supplements; alternative medicines, such as ayurvedics; prescription drugs and over-the-counter drugs, including homeopathic products: Examples of claims observed on these illegally marketed products include:


"Lower your blood sugar naturally." "Lowers A1C levels significantly." "You'll lower your chances of having eye disease, kidney disease, nerve damage and heart disease!" "It can replace medicine in the treatment of diabetes." "For Relief of Diabetic Foot Pain."

Some of the companies also promote unapproved products for other serious diseases, including cancer, sexually transmitted diseases, and macular degeneration.


FDA tested products marketed as "all natural" treatments for diabetes and discovered some of them contained one or more active ingredients found in prescription drugs to treat type 2 diabetes.


Undeclared ingredients can cause serious harm. If consumers and their health care professionals are unaware of the actual ingredients in the products they are taking, these products may interact in dangerous ways with other medications. One possible complication: Patients may end up taking a larger combined dose of the diabetic drugs than they intended, and that may cause a significant unsafe drop in blood sugar levels, a condition known as hypoglycemia.


FDA also looked at sales of prescription drugs from fraudulent online pharmacies. Signs that indicate an online pharmacy is legitimate include: requiring that patients have a valid prescription; providing a physical address in the U.S.; being licensed by a state pharmacy board; and having a state-licensed pharmacist to answer questions. Some fraudulent online pharmacies illegally sell drugs that are not approved in the United States, or sell prescription drug products without meeting necessary requirements.


One website that is subject to a warning letter shipped a prescription diabetes drug without requiring a prescription, and even included an unsolicited free sample of a prescription drug for erectile dysfunction. Moreover, the prescription diabetes drug was dispensed without the medication guide and other precautions required by FDA to ensure the drug is used safely and appropriately.


Although some of these websites may offer for sale what appear to be FDA-approved prescription drugs, FDA cannot confirm that the manufacture or the handling of these drugs follows U.S. regulations or that the drugs are safe and effective for their intended uses. Also, there is a risk the drugs may be counterfeit, contaminated, expired or otherwise unsafe.


A Far-Reaching Problem

There are 26 million people in the U.S. who have diabetes, including about 7 million who are undiagnosed, according to the Centers for Disease Control and Prevention. Millions more have pre-diabetes, meaning they have higher than normal blood sugar levels and can reduce their risks of developing diabetes through healthy lifestyle changes, including diet and exercise.


July 23, 2013

"Products that promise an easy fix might be alluring, but consumers are gambling with their health. In general, diabetes is a chronic disease, but it is manageable and people can lower their risk for developing complications by following treatments prescribed by health care professionals, carefully monitoring blood sugar levels, and sticking to an appropriate diet and exercise program," said Coody.


Health care professionals and consumers are encouraged to report any adverse events related to products intented to treat or cure diabetes to FDA's MedWatch Safety Information and Adverse Event Reporting Program:


This article appears on FDA's Consumer Updates page, which features the latest on all FDA-regulated products.


Incidence of Diabetes and SNAP Payments

National Agricultural and Rural Development Center The government's centerpiece nutrition program could be part of an effort to reduce the incidence of type 2 diabetes in the United States, two researchers say. And rural counties might be the best place to start such a program.


Scott Loveridge (Michigan State University) and Adam Reimer (National Agricultural and Rural Development Policy Center) tracked down the counties that have high rates of diabetes and high per-capita expenditures on SNAP (the Supplemental Nutrition Assistance Program, what we used to call food stamps). ( The researchers' full report is available here.)


The map at the top shows the U.S. counties with the best and worst rates of diabetes (worst are in red, best are in green). The second map shows the counties with the highest and lowest per capita rates of SNAP disbursements (highest, red; lowest, green). And the bottom map shows where the highest diabetes rates and highest per capita SNAP payments overlap. (Click the maps to enlarge them.)


The researchers point out that this geographic relationship between SNAP and diabetes doesn't mean the nutrition program is responsible for diabetes, or even that SNAP recipients have diabetes. They just note that the juxtaposition of diabetes and SNAP might create an opportunity for a new way of handling a public health problem.


Namely, these counties would be ideal locations to test whether giving SNAP vendors incentives to sell healthy food might improve the diabetes rate in the long run.


The rural nature of these counties is an advantage for launching a pilot program, Loveridge and Reimerthey say, because it would be less expensive to administer, smaller and easier to measure.


Rather than placing restrictions on SNAP purchases that require customers to buy healthy foods, Loveridge and Reimerthey suggest a SNAP incentive program. Such a program could provide a little extra profit margin to grocers for healthy foods. That, in turn, might lead vendors to change store layouts, train staff differently and even "upsell" healthy foods like fruits and vegetables.


Loveridge and Reimerthey note that fast-food restaurants make sure customers have plenty of opportunities to purchase high-margin foods like french fries. That's why we always hear the same phrases from the clerk when we place a fast-food order.


If Loveridge and Reimerthey's idea takes off, we might hear something different at the grocery store.


Would you like any fresh tomatoes with that?


National diabetes prevention program offered in Doña Ana County

Posted: 07/22/2013 01:21:03 PM MDT



Seven percent of New Mexico's adults 18 or older have been told by health professionals that they are pre-diabetic or are at high risk for type 2 diabetes, according to the New Mexico Department of Health.


New Mexico State University's Cooperative Extension Service is partnering with Molina Healthcare to provide the Centers for Disease Control and Prevention's National Diabetes Prevention Program to help participants adopt healthy lifestyle habits.


The evidence-based, lifestyle intervention program featuring curriculum based on clinical research and presented by trained lifestyle coaches will be offered in Doña Ana and Bernalillo counties beginning in July.


"If a person has a family member with diabetes, it is not inevitable that they will get diabetes if they work to turn around their eating and exercise habits," said Lucinda Banegas-Carreon, NMSU coordinator of the program. "With the information and encouragement provided by our lifestyle coaches, we hope the participants in the program will have the tools to make the necessary steps to delay or prevent diabetes."


Participants will attend 16 weekly coaching sessions focused on healthy eating, physical activity, and stress reduction, followed by six monthly maintenance sessions. The lifestyle coaches will help lead the supportive group setting that consists of 20 participants per class.


"We are offering tools and information that can be shared and utilized throughout a family," Banegas-Carreon said. "Topics of the weekly sessions will include using MyPlate guidelines for a nutritional meal, understanding the information on food labels and the correlation between fats and cholesterol."


To qualify for the program the participants must be at least 18 years old, be overweight, and meet one or more of the following criteria:


-- Fasting blood glucose 100 to 125 mg/dl


-- Two-hour glucose range 140 to 199 mg/dl


-- HbA1c between 5.7 and 6.4


-- History of gestational diabetes.


"Participants will either be referred by their doctor, or may apply personally," Banegas-Carreon said. "Those not referred by their doctor will answer a group of screening questions asked by our lifestyle coaches."


Classes will be available in Las Cruces, Chaparral and Albuquerque starting this month. For more information about the program or class registration, call 575-646-2034 or 1-877-993-3637.


The National Diabetes Prevention Program is part of a cooperative agreement between CDC and the America's Health Insurance Plans. AHIP is working with four member health plans -- Molina Healthcare, Aetna, EmblemHealth and Florida Blue -- to implement the program in New Mexico, Florida, New York and Texas.


For more information about the National Diabetes Prevention Plan, visit cdc.gov/diabetes/prevention.


Jane Moorman writes for NMSU Communications and can be reached at 505-249-0527.